Cal 101 idelalisib

The treatment with PI3K inhibitor CAL‐101/idelalisib (5–20 μM; Selleckchem) was performed as described in a recent study of Varano et al (2017).

Chronic lymphocytic leukaemia cells were cultured in RPMI‐1640 medium containing soluble 10 ng/mL interleukin (IL)‐4 and CD40 ligand (CD40L or CD154) to mimic the microenvironment of proliferation centres3, 4 as previously described.17 Cells were incubated for 24 hours in these conditions before applying any treatments. Human CLL cell line MEC‐1 was cultured as previous described.17 Goat F(ab’)2 anti‐human IgM was purchased from Bio‐Rad (Hercules, CA, USA), recombinant human BAFF (soluble) was purchased from Enzo (Farmingdale, NY, USA). CUDC‐907, IMD‐0354, ABT‐199, Ibrutinib, Entospletinib, CAL‐101/idelalisib, and PLX‐4720 were obtained from Selleckchem (Houston, TX, USA). HCT116 colon cancer cells were cultured in DMEM medium containing 10% of FCS and penicillin/streptomycin (50 U/mL).

Syk inhibitor (R406; 3 µM) and PI3Kδ inhibitor (Idelalisib CAL-101; 3 µM) were from Selleckchem. SHP-1 inhibitor (TPI-1; 3 µM) and SHP-2 inhibitor (SHP099; 10 µM) were from MedChem Express. Fc-block reagent was purchased from Miltenyi Biotech.